Research progress of bortezomib therapy in patients with relapsed or refractory mantle cell lymphoma
10.3760/cma.j.issn.1009-9921.2011.05.022
- VernacularTitle:硼替佐米治疗复发难治性套细胞淋巴瘤的研究进展
- Author:
Yang DING
;
Xiaomeng WANG
- Publication Type:Journal Article
- Keywords:
Lymphoma,mantle-cell;
Bortezomib;
Therapy
- From:
Journal of Leukemia & Lymphoma
2011;20(5):314-316
- CountryChina
- Language:Chinese
-
Abstract:
Currently refractory and relapsed mantle cell lymphoma (MCL) continues to develope a poor prognosis, and the treatment remains a significant clinical challenge. The use of bortezomib in clinic provides a novel method for the treatment of refractory and relapsed MCL. This review summarizes the mechanism and efficiency of bortezomib in the treatment of MCL and the strategies for overcome of bortezomib resistance.
